FrancophonIA/ELRC3.0 huggingface dataset:
English: Efficacy data are available which demonstrate that this vaccine can be administered at least 14 days before or after the administration of MERIAL non-adjuvanted vaccine against feline leukaemia.
Slovenian: Na podlagi razpoložljivih podatkov o učinkovitosti se lahko to cepivo daje vsaj 14 dni prej ali po dajanju MERIALovega neadjuviranega cepiva proti mačji levkozi.
English: Administer one dose of 1 ml according to the following vaccination scheme: Primary vaccination course: 1 injection from 12 weeks of age, Revaccination: 1 year after primary vaccination, then at intervals of up to 3 years.
Slovenian: Injicirajte 1 odmerek (1 ml) cepiva subkutano po naslednjem razporedu: Osnovno cepljenje: 1 odmerek od dvanajstega tedna starosti Revakcinacija: 1 leto po osnovnem cepljenju, potem v intervalih do 3 let.
English: Duration of immunity after revaccination: 3 years.
Slovenian: Trajanje imunosti po revakcinaciji: tri leta.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Box of 10 vials of suspension for injection Box of 50 vials of suspension for injection Box of 2 vials of suspension for injection
Slovenian: PODATKI NA ZUNANJI OVOJNINI Škatla z 10 vialamisuspenzije za injiciranje Škatla s 50 vialamisuspenzije za injiciranje Škatla z 2 vialamisuspenzije za injiciranje
English: SPECIAL WARNING, IF NECESSARY
Slovenian: POSEBNO(A) OPOZORILO, ČE JE/SO POTREBNO(A)
English: Pregnancy and lactation: The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Slovenian: Brejost in laktacija: Varnost zdravila v obdobju brejosti in laktacije ni bila ugotovljena.
English: As a consequence, the vaccine stimulates active immunity against rabies virus in cats.
Slovenian: Posledica tega je, da cepivo vzpodbudi imunski odgovor proti virusu stekline pri mačkah.
English: Purevax Rabies suspension for injection
Slovenian: Purevax Rabies suspenzija za injiciranje
English: Onset of immunity: 4 weeks after the primary vaccination course.
Slovenian: Nastop imunosti : 4 tedne po osnovnem cepljenju.
English: Do not mix with any other veterinary medicinal product except those mentioned above.
Slovenian: Ne mešajte z nobenim drugim zdravilom razen z MERIALovimi neadjuviranimi cepivi, navedenimi zgoraj.
English: DOSAGE FOR EACH SPECIES, ROUTEAND METHOD OF ADMINISTRATION
Slovenian: ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT IN NAČIN UPORABE
English: Veterinary surgeons may wish to consider two vaccinations.
Slovenian: Veterinarji lahko zato živali cepijo dvakrat.
English: Name and address of the manufacturers of the biological active substance
Slovenian: Ime in naslov izdelovalcev biološke zdravilne učinkovine .
English: Shelf life after first opening the container: use immediately.
Slovenian: Rok uporabnosti po prvem odpiranju stične ovojnine: Uporabite takoj.
English: Duration of immunity after primary vaccination: 1 year.
Slovenian: Trajanje imunosti po osnovnem cepljenju eno leto.
English: Box of 2 or 10 or 50 vials of 1 dose.
Slovenian: Škatla z 2 ali 10 ali 50 vialami z 1 odmerkom.
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Slovenian: B. POGOJI GLEDE OSKRBE IN UPORABE
English: MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Slovenian: IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJE
English: Most of these reactions were noted during the 2 days following the vaccine injection.
Slovenian: Večina opisanih neželenih učinkov je bila opažena v 2 dneh po cepljenju.
English: STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT
Slovenian: NAVEDBA ZDRAVILNE UČINKOVINE IN DRUGIH SESTAVIN
English: Vaccine against rabies infection.
Slovenian: Cepivo proti steklini.
English: SC
Slovenian: S.C.
English: A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Slovenian: A. IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC,
English: EU/2/10/117/001 (10 vials) EU/2/10/117/002 (50 vials) EU/2/10/117/003 (2 vials)
Slovenian: EU/2/10/117/002 (50 stekleničk)
English: Rabies recombinant canarypox virus (vCP65) .............................................................. ≥ 10 6.8 FAID*50 *Fluorescent assay infectious dose 50 %
Slovenian: Rekombinantni poxvirus kanarčkov, ki vsebuje antigen virusa stekline (vCP65) ........... ≥ 10 6,8 FAID*50 *50 % infektivni odmerek v fluorescenčnem testu
English: 1 ml contains: Rabies recombinant canarypox virus (vCP65) ................................................................. ≥ 106.8 FAID50
Slovenian: Rekombinantni poxvirus kanarčkov, ki vsebuje antigen virusa stekline (vCP65) ......................... ≥ 10 6,8
English: No adverse reactions other than those already mentioned in section 4.6 have been observed after the administration of 10 doses.
Slovenian: Po vnosu 10 odmerkov cepiva niso opazili nobenih drugih neželenih učinkov razen tistih, navedenih v poglavju 4.6.
English: EXP (month/year) Once broached, use immediately.
Slovenian: EXP {mesec/leto} Po odprtju uporabite takoj.
English: Box of 50 vials of 1 dose.
Slovenian: Škatla s 50 vialamiz 1 odmerkom.
English: METHOD AND ROUTE OF ADMINISTRATION
Slovenian: NAČIN IN POTUPORABE
English: Box of 2 vials of 1 dose.
Slovenian: Škatla z 2 vialamiz 1 odmerkom.
English: Box of 10 vials of 1 dose.
Slovenian: Škatla z 10 vialamiz 1 odmerkom.
English: Shelf life of the veterinary medicinal product as packaged for sale: 18 months.
Slovenian: Rok uporabnosti zdravila v pakiranju za prodajo: 18 mesecev Rok uporabnosti po prvem odpiranju stične ovojnine: Uporabite takoj.
English: PACKAGE LEAFLET FOR:
Slovenian: 1 ml vsebuje:
English: EU number Invented name
Slovenian: EU številka Izmišljeno ime
English: Concentrate: 2 ml Solvent: 100 ml
Slovenian: koncentrat: 2 ml vehikel: 100 ml
English: 1 vial concentrate
Slovenian: 1 viala koncentrata
English: Solvent: vial (glass)
Slovenian: vehikel: viala (steklo)
English: 1 pre-loaded injection device
Slovenian: 1 napolnjen injektor
English: Subcutaneous Preloaded injection device, (hypodermic needle covered with a protective cap)
Slovenian: 1 viala vehikla nič dni implantat psi subkutana uporaba napolnjen injektor (igla za podkožno dajanje z zaščitnim pokrovčkom)
English: EU/2/03/040/001 Gonazon 1,600 microgram/ml
Slovenian: EU/2/03/040/001 Gonazon 1.600 mikrogramov/ml koncentrat in vehikel za raztopino za injiciranje plemenke salmonidnih vrst rib intraperitonealno koncentrat: viala (steklo)
English: Not applicable
Slovenian: Navedba ni smiselna.
English: Tmax is between 3 and 8 hours.
Slovenian: tmax je med 3 in 8 urami.
English: Diagnosis should be made according to current guidelines.
Slovenian: Diagnozo je potrebno postaviti skladno z veljavnimi smernicami.
English: In another case of a large overdose, the patient also survived and recovered.
Slovenian: V nekem drugem primeru velikega čezmernega odmerka je bolnik prav tako preživel in okreval.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 22 April 2013
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve pridobitve dovoljenja: 22. april 2013
English: Date of latest renewal: 08 January 2018
Slovenian: Datum zadnjega podaljšanja: 08 januar 2018
English: D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Slovenian: D. POGOJI ALI OMEJITVE GLEDE VARNE IN UČINKOVITE UPORABE ZDRAVILA
English: Some factors that may raise urine pH (see section 5.2 “Elimination”) may necessitate careful monitoring of the patient.
Slovenian: Zaradi nekaterih dejavnikov, ki lahko zvišajo pH urina (glejte poglavje 5.2 »Izločanje«) je potreben skrben nadzor bolnika.
English: See section 4.
Slovenian: Poglavje 4.
English: In case of signs and symptoms of general central nervous system (CNS) overstimulation, careful symptomatic clinical treatment should be considered.
Slovenian: Pri znakih in simptomih splošne čezmerne stimulacije centralnega živčnega sistema (CŽS) je treba razmisliti o previdnem simptomatičnem kliničnem zdravljenju.
English: 1 Hallucinations have mainly been observed in patients with severe Alzheimer´s disease.
Slovenian: 1Halucinacije so bile večinoma opažene pri bolnikih s hudo Alzheimerjevo boleznijo.
English: ANNEX II A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Slovenian: PRILOGA II A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE GLEDE VARNE IN UČINKOVITE UPORABE ZDRAVILA
English: Children and adolescents Memantine Mylan is not recommended for children and adolescents under the age of 18 years.
Slovenian: Otroci in mladostniki Zdravila Memantin Mylan ne priporočajo otrokom in mladostnikom, mlajšim od 18 let.
English: Memantine should not be used during pregnancy unless clearly necessary.
Slovenian: Memantina se ne sme uporabljati med nosečnostjo, razen, če je nujno potrebno.
English: “Possible side effects”.
Slovenian: »Možni neželeni učinki«.
English: Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Slovenian: V posameznih razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti.
English: Memantine is eliminated in a monoexponential manner with a terminal t½ of 60 to 100 hours.
Slovenian: Memantin se izloča na monoekspotentni način s končnim razpolovnim časom (t½) od 60 do 100 ur.
English: Adverse reactions are ranked according to system organ class, using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Slovenian: Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjega dogovora: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
English: Psychotic reactions2
Slovenian: Neznana psihotične reakcije2
English: Elevated liver function test
Slovenian: Pogosti povečane vrednosti testov jetrne funkcije
English: No specific antidote for intoxication or overdose is available.
Slovenian: Antidota za zastrupitev ali preveliko odmerjanje ni.
English: It modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction.
Slovenian: Modulira učinke patološko povečanih toničnih vrednosti glutamata, ki lahko vodijo v nevronsko disfunkcijo.
English: These compounds act at the same receptor system as memantine, and therefore adverse reactions (mainly central nervous system (CNS)-related) may be more frequent or more pronounced (see also section 4.5).
Slovenian: Te snovi delujejo na isti receptorski sistem kot memantin, zato so lahko neželeni učinki (zlasti na centralni živčni sistem (CŽS)) pogostejši in bolj izraženi (glejte tudi poglavje 4.5).
English: The patient received symptomatic treatment and plasmapheresis.
Slovenian: Bolnika so zdravili simptomatsko in tudi s plazmaferezo.
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Slovenian: B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovaje in izdaja zdravila je le s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2)
English: There is increasing evidence that malfunctioning of glutamatergic neurotransmission, in particular at NMDA-receptors, contributes to both expression of symptoms and disease progression in neurodegenerative dementia.
Slovenian: Vse več je dokazov, da motnje v delovanju glutamatnega živčnega prenosa, še posebno preko receptorjev NMDA, prispevajo tako k izraženosti simptomov kot k napredovanju nevrodegenerativne demence.
English: If you forget to take Memantine Mylan - If you find you have forgotten to take your dose of Memantine Mylan, wait and take your next dose at the usual time.
Slovenian: Če ste pozabili vzeti zdravilo Memantin Mylan - Če ste ugotovili, da ste pozabili vzeti predpisani odmerek zdravila Memantin Mylan, počakajte in naslednji odmerek vzemite ob običajnem času.
English: Relative large overdoses (200 mg and 105 mg/day for 3 days, respectively) have been associated with either only symptoms of tiredness, weakness and/or diarrhoea or no symptoms.
Slovenian: Sorazmerno veliki čezmerni odmerki (200 mg na dan oziroma 105 mg na dan, tri dni) so bili povezani samo s simptomi utrujenosti, šibkosti in/ali driske ali pa simptomov sploh ni bilo.
English: Not known (frequency cannot be estimated from the available data): • Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions
Slovenian: Neznana pogostnost (pogostosti iz razpoložljivih podatkov ni mogoče oceniti): • vnetje trebušne slinavke, vnetje jeter (hepatitis) in psihotične reakcije
English: Do not take Memantine Mylan: - if you are allergic to memantine or any of the other ingredients of this medicine (listed in section 6).
Slovenian: Ne jemljite zdravila Memantin Mylan: - če ste alergični na memantin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: Generics [UK] Limited Station Close, Potters Bar, Hertfordshire EN6 1TL, United Kingdom.
Slovenian: Generics [UK] Limited Station Close, Potters Bar, Hertfordshire EN6 1 TL, Velika Britanija
English: Linearity Studies in volunteers have demonstrated linear pharmacokinetics in the dose range of 10 to 40 mg.
Slovenian: Študije na zdravih prostovoljcih so pokazale, da ima memantin linearno farmakokinetiko v razponu odmerkov od 10 do 40 mg.
English: If tolerated well after at least 7 days of treatment, the dose could be increased up to 20 mg/day according to standard titration scheme.
Slovenian: Če bolnik zdravljenje dobro prenaša, se lahko odmerek po najmanj 7 dneh zdravljenja zviša do 20 mg na dan, po standardni titracijski shemi.
English: Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V*.
Slovenian: Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
English: As a consequence, only limited data are available and patients with these conditions should be closely supervised.
Slovenian: Posledično je za bolnike z omenjenimi obolenji na voljo le omejeno število podatkov, zato je priporočljiv skrben nadzor teh bolnikov.
English: 2 Isolated cases reported in post-marketing experience.
Slovenian: 2Posamezni primeri, o katerih so poročali v okviru izkušenj v obdobju trženja zdravila.
English: Caution is recommended in patients with epilepsy, former history of convulsions or patients with predisposing factors for epilepsy.
Slovenian: Previdnost se priporoča pri bolnikih z epilepsijo, s krči v anamnezi ali pri bolnikih z nagnjenostjo k epilepsiji.
English: There is one published case report on a possible risk also for the combination of memantine and phenytoin.
Slovenian: Na voljo je tudi objavljen klinični primer o morebitnem tveganju pri sočasni uporabi memantina in fenitoina.
English: 1, Hungary.
Slovenian: 1, Madžarska
English: Very rare (may affect up to 1 in 10,000 people): • Seizures
Slovenian: Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): • epileptični napadi
English: The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory.
Slovenian: V možganih se nahajajo tako imenovani receptorji N-metil-D-aspartata (NMDA), ki sodelujejo v prenosu živčnih signalov, pomembnih za učenje in spomin.
English: BATCH NUMBER Lot
Slovenian: ŠTEVILKA SERIJE LOT
English: In volunteers with normal kidney function, total clearance (Cltot) amounts to 170 ml/min/1.73 m2 and part of total renal clearance is achieved by tubular secretion.
Slovenian: Pri prostovoljcih z normalnim delovanjem ledvic je celoten očistek (Cltot) 170 ml/min/1,73 m²; del celotnega ledvičnega očistka je dosežen s tubularno sekrecijo.
English: The most frequently occurring adverse reactions with a higher incidence in the memantine group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
Slovenian: Najpogostejši neželeni učinki, ki so se pogosteje pojavili pri skupini bolnikov, ki je jemala memantin, kot pri skupini, ki je prejemala placebo, so bili: omotica (6,3 % proti 5,6 %), glavobol (5,2 % proti 3,9 %), zaprtje (4,6 % proti 2,6 %), zaspanost (3,4 % proti 2,2 %) in hipertenzija (4,1 % proti 2,8 %).
English: Pregnancy The use of memantine in pregnant women is not recommended.
Slovenian: Nosečnost Uporaba memantina pri nosečnicah ni priporočljiva.
English: • Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and nicotine that use the same renal cationic transport system as amantadine may also possibly interact with memantine leading to a potential risk of increased plasma levels.
Slovenian: • Ostale učinkovine, kot so cimetidin, ranitidin, prokainamid, kinidin, kinin in nikotin, ki uporabljajo isti ledvični kationski transportni sistem kot amantadin, prav tako lahko medsebojno reagirajo z memantinom, kar lahko vodi do povišanih vrednosti v plazmi.
English: In the prospectively defined primary analysis statistical significance was not reached at the primary efficacy endpoint at week 24.
Slovenian: V prospektivno opredeljeni primarni analizi v 24. tednu ni bilo statistično značilnih razlik pri primarnih ciljih študije.
English: Memantine Mylan should be administered orally once a day and should be taken at the same time every day.
Slovenian: Zdravilo Memantin Mylan je treba jemati peroralno enkrat dnevno ter ga zaužiti vsak dan ob istem času.
English: In a study using orally administered 14C-memantine, a mean of 84% of the dose was recovered within 20 days, more than 99% being excreted renally.
Slovenian: V študiji s peroralnim memantinom 14C se je v 20 dneh izločilo povprečno 84 % odmerka, od tega več kot 99 % preko ledvic.
English: Memantine was not teratogenic in rats and rabbits, even at maternally toxic doses, and no adverse effects of memantine were noted on fertility.
Slovenian: Memantin ni bil teratogen pri podganah in zajcih, tudi pri odmerkih, toksičnih za mater, prav tako pa niso opazili neželenih učinkov na rodnost.
English: What Memantine Mylan is and what it is used for What you need to know before you take Memantine Mylan How to take Memantine Mylan Possible side effects
Slovenian: Kaj je zdravilo Memantin Mylan in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Memantin Mylan Kako jemati zdravilo Memantin Mylan Možni neželeni učinki
English: In patients with mild or moderate hepatic impaired function (Child-Pugh A and Child-Pugh B), no dose adjustment is needed.
Slovenian: Pri bolnikih z blago ali zmerno jetrno okvaro (Child-Pugh A in Child-Pugh B) prilagoditev odmerjanja ni potrebna.
English: If you go into hospital, let your doctor know that you are taking Memantine Mylan.
Slovenian: V primeru, da ste sprejeti v bolnišnico, obvestite zdravnika, da jemljete zdravilo Memantin Mylan.
English: - If you take a large overdose of Memantine Mylan, contact your doctor or get medical advice, as you may need medical attention.
Slovenian: - Če ste zaužili prevelik odmerek zdravila Memantin Mylan, obvestite zdravnika, ker boste morda potrebovali zdravniško obravnavo.
English: What Memantine Mylan is and what it is used for
Slovenian: Kaj je zdravilo Memantin Mylan in za kaj ga uporabljamo
English: On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg film-coated tablets or one 20 mg film-coated tablet once a day) as described above.
Slovenian: Na podlagi kliničnih študij je priporočeni odmerek za bolnike, starejše od 65 let, 20 mg na dan (dve 10-miligramski filmsko obloženi tableti ali eno 20-miligramsko filmsko obloženo tableto enkrat na dan), kot je opisano zgoraj.
English: Furthermore, memantine has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.
Slovenian: Tudi memantin lahko blago ali zmerno vpliva na sposobnost vožnje in upravljanja strojev, zato je potrebno bolnike opozoriti, da morajo biti posebno previdni.
English: It is not known whether memantine is excreted in human breast milk but, taking into consideration the lipophilicity of the substance, this probably occurs.
Slovenian: Ni znano ali se memantin izloča v materino mleko, vendar bi iz njegove lipofilnosti lahko sklepali, da se.
English: Moderate to severe Alzheimer's disease usually causes impairment of driving performance and compromises the ability to use machinery.
Slovenian: Zmerna do huda Alzheimerjeva bolezen je običajno vzrok za nesposobnost vožnje in upravljanja strojev.
English: Concomitant administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify their effects and a dose adjustment may be necessary.
Slovenian: Sočasno dajanje memantina in spazmolitikov, dantrolena ali baklofena lahko spremeni njihove učinke, zato bo morda potrebna prilagoditev odmerkov.
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Slovenian: Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu.
English: In particular, Memantine Mylan may change the effects of the following medicines and their dose may need to be adjusted by your doctor: - amantadine, ketamine, dextromethorphan - dantrolene, baclofen - cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine - hydrochlorothiazide (or any combination with hydrochlorothiazide) - anticholinergics (substances generally used to treat movement disorders or intestinal cramps) - anticonvulsants (substances used to prevent and relieve seizures) - barbiturates (substances generally used to induce sleep) - dopaminergic agonists (substances such as L-dopa, bromocriptine) - neuroleptics (substances used in the treatment of mental disorders) - oral anticoagulants
Slovenian: Posebno v primeru, če skupaj z zdravilom Memantin Mylan jemljete naslednja zdravila, se lahko njihovi učinki spremenijo in bo zdravnik morda moral prilagoditi odmerek: - amantadin, ketamin, dekstrometorfan - dantrolen, baklofen - cimetidin, ranitidin, prokainamid, kinidin, kinin, nikotin - hidroklorotiazid (ali kombinacije zdravil, ki vsebujejo hidroklorotiazid) - antiholinergiki (zdravila, ki se običajno uporabljajo za zdravljenje motenj gibanja in trebušnih krčev) - antikonvulzivi (zdravila za preprečevanje ali lajšanje epileptičnih krčev) - barbiturati (zdravila, ki se na splošno uporabljajo kot uspavala) - dopaminergični agonisti (učinkovine kot so L-dopa, bromokriptin) - nevroleptiki (zdravila za zdravljenje duševnih motenj) - peroralni antikoagulanti
English: Although no causal relationship has been established, close monitoring of prothrombin time or INR is advisable for patients concomitantly treated with oral anticoagulants.
Slovenian: Čeprav vzročna povezanost ni bila dokazana, je pri bolnikih, ki se sočasno zdravijo s peroralnimi antikoagulanti, priporočljivo spremljanje protrombinskega časa ali INR.
English: Hallucinations1
Slovenian: Občasni halucinacije1